RT Journal Article
SR Electronic
T1 The use of a deep learning model in the histopathological diagnosis of actinic keratosis: A case control accuracy study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.20.23298649
DO 10.1101/2023.11.20.23298649
A1 Balkenhol, J.
A1 Schmidt, M.
A1 Schnauder, T.
A1 Langhorst, J.
A1 Arrastia, J. Le’Clerc
A1 Baguer, D. Otero
A1 Gilbert, G.
A1 Schmitz, L.
A1 Dirschka, T.
YR 2023
UL http://medrxiv.org/content/early/2023/11/20/2023.11.20.23298649.abstract
AB Actinic Keratosis (AK) is a frequent dermatological diagnosis which contributes to a large proportion of routine dermatopathology. A current development in histopathology is in the digitization of specimens by creating whole slide images (WSI) with slide scanners. Deep Learning Models (DLM) have been introduced to radiology or pathology for image recognition but dermatopathology lacks available solutions. Building on previous work about skin pathologies, this paper proposes a DLM following the U-Net architecture to detect AK in histopathological samples. In total, 297 histopathological slides (269 with AK and 28 without AK) have been retrospectively selected. They were randomly assigned to training, validation, and testing groups. Performance was evaluated by conducting a Case Control Accuracy Study on three levels of granularity. The DLM model achieved an overall accuracy of 99.13% on the WSI level, 99.02% on the patch level and an intersection over union (IoU) of 83.88%. The proposed DLM reliably recognizes AK in histopathological images, supporting the implementation of DLMs in dermatopathology practice. Given existing technical capabilities and advancements, DLMs could have a significant influence on dermatopathology routine in the future.Competing Interest StatementJ. Balkenhol: none; L. Schmitz: Honoraria from Almirall, Beiersdorf, Biofrontera, Galderma, Mylan, Sanofi; T. Dirschka: Lecture fees from Almirall, Biofrontera, Galderma, Leo, Meda, Riemser, Janssen; member of advisory boards for Almirall, Biofrontera, infectopharm, Leo, Meda, Novartis, Riemser, Janssen; unrestricted grants from Meda and Galderma; Tim Schnauder: none; Johannes Langhorst: none; Maximilian Schmidt: German Federal Ministry for Economic Affairs and Climate Action (BMWK) and the European Social Fund (ESF); Daniel Otero Baguer: German Federal Ministry for Economic Affairs and Climate Action (BMWK) and the European Social Fund (ESF); Jean Le Clerc Arrastia: German Federal Ministry for Economic Affairs and Climate Action (BMWK) and the European Social Fund (ESF); G. Gilbert: noneFunding StatementM Schmidt, D. Otero Baguer, and J. Le Clerc Arrastia acknowledge the financial support by the German Federal Ministry for Economic Affairs and Climate Action (BMWK) and the European Social Fund (ESF) within the EXIST Transfer of Research project aisencia'.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was performed in accordance with the approval of the ethics committee of the University Witten-Herdecke (Proposal-No. 105/2022). The study retrospectively analyzes patient samples that have been gained in the clinical routine and have been processed in an anonymized way.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAffiliates of the Centroderm Clinic1 have unlimited access to all clinical data used in this research work. Affiliates of the University of Bremen4 and aisencia5 have unlimited access to all technical data. Both affiliates share a pool of information for the collaboration. Clinical data of the included Actinic Keratoses are available in the published data set (Balkenhol, Julius; Schmidt, Maximillian; Schnauder, Tim; Langenhorst, Johannes; Le Clerc Arrastia, Jean; Otero Baguer, Daniel; Gilbert, Georgia; Schmitz, Lutz; Dirschka, Thomas (2023), Supplementary Data 1.0: The use of a deep learning model in the histopathological diagnosis of actinic keratosis: A case control accuracy study, Mendeley Data, V2, doi: 10.17632/2t5pg25vkh.2). Histopathological slides and annotations cannot be made publicly available. Access to view the slides and annotations can be given upon request to the authors. https://data.mendeley.com/datasets/2t5pg25vkh/2 AKActinic keratosesANNArtificial neural networksDNNDeep neural networksDLMsDeep learning modelsAIArtificial intelligenceSKSeborrheic keratosisMBMorbus BowenWSIWhole slide imagePPVPositive predictive valueNPVNegative predictive valueXAIExplainable Artificial IntelligenceIoUIntersection over union